Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC).
For more information, please visit ClinicalTrials.gov
|Patient Population||Investigational Product(s)||Phase||Status|
|Oral Mucositis||Cobiprostone||II||Open and Accruing|